120 related articles for article (PubMed ID: 17689900)
1. In vivo distribution of arsonoliposomes: effect of vesicle lipid composition.
Zagana P; Haikou M; Klepetsanis P; Giannopoulou E; Ioannou PV; Antimisiaris SG
Int J Pharm; 2008 Jan; 347(1-2):86-92. PubMed ID: 17689900
[TBL] [Abstract][Full Text] [Related]
2. Trypanocidal activity of arsonoliposomes: effect of vesicle lipid composition.
Zagana P; Klepetsanis P; Ioannou PV; Loiseau PM; Antimisiaris SG
Biomed Pharmacother; 2007 Sep; 61(8):499-504. PubMed ID: 17606357
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of PEG-lipids in arsonoliposomes results in formation of highly stable arsenic-containing vesicles.
Piperoudi S; Fatouros D; Ioannou PV; Frederik P; Antimisiaris SG
Chem Phys Lipids; 2006 Feb; 139(2):96-106. PubMed ID: 16405880
[TBL] [Abstract][Full Text] [Related]
4. In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice.
Antimisiaris SG; Klepetsanis P; Zachariou V; Giannopoulou E; Ioannou PV
Int J Pharm; 2005 Jan; 289(1-2):151-8. PubMed ID: 15652207
[TBL] [Abstract][Full Text] [Related]
5. Does the lipid membrane composition of arsonoliposomes affect their anticancer activity? A cell culture study.
Zagana P; Haikou M; Giannopoulou E; Ioannou PV; Antimisiaris SG
Mol Nutr Food Res; 2009 May; 53(5):592-9. PubMed ID: 18727012
[TBL] [Abstract][Full Text] [Related]
6. Arsonoliposomes: effect of lipid composition on their stability and morphology.
Piperoudi S; Ioannou PV; Frederik P; Antimisiaris SG
J Liposome Res; 2005; 15(3-4):187-97. PubMed ID: 16393910
[TBL] [Abstract][Full Text] [Related]
7. The effect of pH on the electrophoretic behaviour of a new class of liposomes: arsonoliposomes.
Fatouros DG; Klepetsanis P; Ioannou PV; Antimisiaris SG
Int J Pharm; 2005 Jan; 288(1):151-6. PubMed ID: 15607267
[TBL] [Abstract][Full Text] [Related]
8. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
9. Arsonoliposome interaction with thiols: effect of pegylation and arsonolipid content of arsonoliposomes on their integrity during incubation in glutathione.
Haikou MN; Zagana P; Ioannou PV; Antimisiaris SG
J Nanosci Nanotechnol; 2006; 6(9-10):2974-8. PubMed ID: 17048506
[TBL] [Abstract][Full Text] [Related]
10. Arsonoliposomes: preparation and physicochemical characterization.
Antimisiaris SG; Ioannou PV
Methods Mol Biol; 2010; 605():147-62. PubMed ID: 20072879
[TBL] [Abstract][Full Text] [Related]
11. Arsonoliposomes: novel nanosized arsenic-containing vesicles for drug delivery.
Fatouros DG; Ioannou PV; Antimisiaris SG
J Nanosci Nanotechnol; 2006; 6(9-10):2618-37. PubMed ID: 17048471
[TBL] [Abstract][Full Text] [Related]
12. Physical stability of sonicated arsonoliposomes: effect of calcium ions.
Fatouros DG; Piperoudi S; Gortzi O; Ioannou PV; Frederik P; Antimisiaris SG
J Pharm Sci; 2005 Jan; 94(1):46-55. PubMed ID: 15761929
[TBL] [Abstract][Full Text] [Related]
13. Stability and aggregation studies of non-sonicated arsonolipid-containing vesicles.
Fatouros DG; Bouropoulos N; Ioannou PV; Antimisiaris SG
Cell Mol Biol Lett; 2005; 10(1):173-83. PubMed ID: 15809688
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
[TBL] [Abstract][Full Text] [Related]
15. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes.
Li WM; Xue L; Mayer LD; Bally MB
Biochim Biophys Acta; 2001 Aug; 1513(2):193-206. PubMed ID: 11470091
[TBL] [Abstract][Full Text] [Related]
16. In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice.
Antimisiaris SG; Ioannou PV; Loiseau PM
J Pharm Pharmacol; 2003 May; 55(5):647-52. PubMed ID: 12831507
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
18. Targeted and sustained drug delivery using PEGylated galactosylated liposomes.
Managit C; Kawakami S; Nishikawa M; Yamashita F; Hashida M
Int J Pharm; 2003 Nov; 266(1-2):77-84. PubMed ID: 14559396
[TBL] [Abstract][Full Text] [Related]
19. Haemolytic activity of liposomes: effect of vesicle size, lipid concentration and polyethylene glycol-lipid or arsonolipid incorporation.
Mourtas S; Michanetzis GP; Missirlis YF; Antimisiaris SG
J Biomed Nanotechnol; 2009 Aug; 5(4):409-15. PubMed ID: 20055087
[TBL] [Abstract][Full Text] [Related]
20. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
